HUE061262T2 - Splicing mechanizmust gátló új kémiai molekulák splicing hibákból betegségek kezelésére - Google Patents
Splicing mechanizmust gátló új kémiai molekulák splicing hibákból betegségek kezeléséreInfo
- Publication number
- HUE061262T2 HUE061262T2 HUE10757474A HUE10757474A HUE061262T2 HU E061262 T2 HUE061262 T2 HU E061262T2 HU E10757474 A HUE10757474 A HU E10757474A HU E10757474 A HUE10757474 A HU E10757474A HU E061262 T2 HUE061262 T2 HU E061262T2
- Authority
- HU
- Hungary
- Prior art keywords
- splicing
- inhibit
- treatment
- new chemical
- diseases resulting
- Prior art date
Links
- 230000007547 defect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18655209P | 2009-06-12 | 2009-06-12 | |
| US18654409P | 2009-06-12 | 2009-06-12 | |
| EP09162630A EP2261214A1 (en) | 2009-06-12 | 2009-06-12 | Compounds useful to treat premature aging and in particular progeria |
| EP20090305540 EP2266972A1 (en) | 2009-06-12 | 2009-06-12 | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE061262T2 true HUE061262T2 (hu) | 2023-05-28 |
Family
ID=43309298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10728368A HUE045548T2 (hu) | 2009-06-12 | 2010-06-14 | Rák kezelésére hasznos gyógyszer |
| HUE10757474A HUE061262T2 (hu) | 2009-06-12 | 2010-06-14 | Splicing mechanizmust gátló új kémiai molekulák splicing hibákból betegségek kezelésére |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10728368A HUE045548T2 (hu) | 2009-06-12 | 2010-06-14 | Rák kezelésére hasznos gyógyszer |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US20120277230A1 (hu) |
| EP (6) | EP2440547B1 (hu) |
| JP (8) | JP5905385B2 (hu) |
| KR (14) | KR101863021B1 (hu) |
| CN (13) | CN102596935B (hu) |
| AU (3) | AU2010258214B2 (hu) |
| BR (5) | BR122019013686B1 (hu) |
| CA (5) | CA2764024C (hu) |
| CU (4) | CU24245B1 (hu) |
| DK (4) | DK2440545T3 (hu) |
| ES (4) | ES2940885T3 (hu) |
| FI (3) | FI3517534T3 (hu) |
| HR (3) | HRP20230248T1 (hu) |
| HU (2) | HUE045548T2 (hu) |
| LT (1) | LT2440547T (hu) |
| MX (10) | MX364989B (hu) |
| PL (4) | PL2440547T3 (hu) |
| PT (4) | PT2440545T (hu) |
| RU (1) | RU2567752C2 (hu) |
| SI (1) | SI2440547T1 (hu) |
| TR (1) | TR201910781T4 (hu) |
| WO (3) | WO2010143169A2 (hu) |
| ZA (2) | ZA201109031B (hu) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| HRP20191460T1 (hr) * | 2009-06-12 | 2019-11-15 | Abivax | Spojevi korisni za liječenje raka |
| CU24245B1 (es) * | 2009-06-12 | 2017-02-02 | Centre Nat Rech Scient | QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADAS |
| ES2534226T3 (es) | 2009-09-03 | 2015-04-20 | Bioenergenix | Compuestos heterocíclicos para la inhibición de PASK |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| WO2012094462A2 (en) | 2011-01-05 | 2012-07-12 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| JP6139415B2 (ja) | 2011-03-02 | 2017-05-31 | バイオエナジェニックス | Ｐａｓｋの阻害のための複素環化合物 |
| US8916561B2 (en) | 2011-03-02 | 2014-12-23 | Bioenergenix, Llc | Substituted quinoxaline compounds for the inhibition of PASK |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| FR2987627B1 (fr) | 2012-03-05 | 2016-03-18 | Splicos | Utilisation de rbm39 comme biomarqueur |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US20150133450A1 (en) * | 2012-06-20 | 2015-05-14 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| US9145411B2 (en) | 2012-08-02 | 2015-09-29 | Asana Biosciences, Llc | Substituted amino-pyrimidine derivatives |
| WO2014028479A1 (en) | 2012-08-13 | 2014-02-20 | Envoy Therapeutics, Inc. | Quinoxaline derivatives as gpr6 modulators |
| JP2014237624A (ja) * | 2012-10-23 | 2014-12-18 | 日本曹達株式会社 | ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤 |
| WO2014081953A1 (en) | 2012-11-21 | 2014-05-30 | Richard David J | Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives |
| GB201301571D0 (en) * | 2012-11-27 | 2013-03-13 | Fundanci N Pedro Barri De La Maza | Product and use |
| US20140194465A1 (en) * | 2013-01-04 | 2014-07-10 | Novarx Corporation | Compositions for treatment of cancer |
| EP2757161A1 (en) * | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| PL3016656T3 (pl) * | 2013-07-05 | 2022-02-21 | Abivax | Związki cykliczne użyteczne w leczeniu chorób wywoływanych przez retrowirusy |
| WO2015005491A1 (ja) * | 2013-07-12 | 2015-01-15 | 国立大学法人京都大学 | 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法 |
| WO2015017788A1 (en) | 2013-08-01 | 2015-02-05 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
| EP3063302B1 (en) | 2013-10-30 | 2019-12-04 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
| JO3466B1 (ar) | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| US10179783B2 (en) | 2014-02-14 | 2019-01-15 | Taketa Pharmaceutical Company Limited | Tetrahydropyridopyrazines as modulators of GPR6 |
| EP3848034B1 (en) | 2014-03-26 | 2025-02-12 | Astex Therapeutics Limited | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| DK3122359T3 (da) | 2014-03-26 | 2021-03-08 | Astex Therapeutics Ltd | Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| EP2974729A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| CA2973942C (en) | 2015-01-30 | 2023-07-11 | Centre National De La Recherche Scientifique (Cnrs) | Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| EP3059591A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| KR102691777B1 (ko) | 2015-09-23 | 2024-08-02 | 얀센 파마슈티카 엔브이 | 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도 |
| WO2017050864A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | New compounds |
| JP6941611B2 (ja) | 2015-12-17 | 2021-09-29 | バイオカイン セラピューティックス リミテッド | ケモカイン活性および／または癌細胞成長を阻害するための小分子 |
| WO2017103931A1 (en) * | 2015-12-17 | 2017-06-22 | Biokine Therapeutics Ltd. | Small molecules against cancer |
| CA3010690A1 (en) * | 2016-02-03 | 2017-08-10 | Janssen Pharmaceutica Nv | Tau pet imaging ligands |
| US10464903B2 (en) | 2016-03-18 | 2019-11-05 | Ratiopharm Gmbh | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
| ES2846833T3 (es) | 2016-07-18 | 2021-07-29 | Janssen Pharmaceutica Nv | Ligandos de obtención de imágenes de tau por PET |
| AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| JP2020525459A (ja) * | 2017-06-26 | 2020-08-27 | アンスティテュ・パストゥール | Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置 |
| CN111032629A (zh) * | 2017-08-29 | 2020-04-17 | 朱拉蓬基金会 | 喹啉和萘啶的衍生物和组合物 |
| US12528810B2 (en) * | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| WO2019186277A1 (en) | 2018-03-28 | 2019-10-03 | Institut Pasteur | Ultrasensitive hiv-1 p24 detection assay |
| EP3594206A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3594205A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| EP3669874A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
| WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| EP4524131A1 (en) | 2019-05-15 | 2025-03-19 | AlonBio Ltd. | Small molecules for treating cancer, inhabiting chemokine activity and/or inducing cell death |
| EP3858815A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| CU20220041A7 (es) | 2020-01-31 | 2023-03-07 | Abivax | Dispersión sólida amorfa de 8-cloro-n-(4-(trifluorometoxi)fenil)quinolin-2-amina |
| EP3858336A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| IL296522A (en) | 2020-03-20 | 2022-11-01 | Abivax | Compounds for treating or preventing a coronaviridae infection and methods and uses for assessing the occurrence of a coronaviridae infection |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| EP4620469A3 (en) | 2020-07-02 | 2025-10-01 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| EP4063351A1 (en) | 2021-03-26 | 2022-09-28 | Abivax | Preparation method of quinoline derivative compounds |
| CN117222639A (zh) | 2021-05-27 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | 喹啉胺类化合物、其制备方法及其在医药上的应用 |
| KR20230072900A (ko) | 2021-11-18 | 2023-05-25 | 동우 화인켐 주식회사 | 마이크로 led 구조체 및 이의 제조방법 |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
| TW202333698A (zh) * | 2022-01-24 | 2023-09-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 喹啉胺類化合物、其製備方法及其在醫藥上的應用 |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
| EP4624469A1 (en) | 2022-11-25 | 2025-10-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Quinoline amine compound crystal form and preparation method therefor |
| AU2024318637A1 (en) | 2023-08-01 | 2026-01-22 | Abivax | Obefazimod for treatment of ulcerative colitis |
| CN121532389A (zh) * | 2023-08-30 | 2026-02-13 | 江苏正大丰海制药有限公司 | 用于调节微小rna-124活性的化合物 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR400973A (fr) | 1909-03-19 | 1909-08-13 | Jean Victor Massillon | Nouveau sertisseur à main pour la fabrication des cartouches |
| GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
| BE486034A (hu) | 1947-11-28 | |||
| DE958647C (de) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen |
| FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
| FR2627493B1 (fr) * | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
| FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| WO2000059875A2 (en) | 1999-04-05 | 2000-10-12 | City Of Hope | Novel inhibitors of formation of advanced glycation endproducts (age's) |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| DE10013318A1 (de) * | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| HUP0302793A3 (en) | 2001-01-22 | 2006-01-30 | Memory Pharmaceuticals Corp Mo | N-substituted aniline derivatives useful as phosphodiesterase 4 inhibitors, pharmaceutical compositions containing them and process for their preparations |
| CA2486376A1 (en) | 2002-05-22 | 2003-12-04 | Amgen Inc. | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| RU2368604C2 (ru) * | 2002-07-19 | 2009-09-27 | Мемори Фармасьютиклз Корпорейшн | Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина |
| WO2006081444A2 (en) | 2005-01-28 | 2006-08-03 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
| FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
| WO2004078731A1 (en) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Quinoline-carboxylic acids and the derivatives thereof, a focused library |
| JP2006519846A (ja) | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター：使用および合成の方法 |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| CN1882345A (zh) * | 2003-10-16 | 2006-12-20 | 希龙公司 | 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉 |
| UA84175C2 (ru) * | 2003-11-19 | 2008-09-25 | Аррей Байофарма Инк. | Гетероциклические ингибиторы мэк и их применение |
| WO2006051311A1 (en) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
| JPWO2007000876A1 (ja) | 2005-06-29 | 2009-01-22 | 株式会社Adeka | 樹脂添加剤組成物及びその樹脂組成物 |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| WO2008008234A1 (en) * | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| BRPI0806898A2 (pt) * | 2007-01-19 | 2015-07-14 | Ardea Biosciences Inc | Inibidores de mek |
| FR2912745A1 (fr) * | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
| US20100249184A1 (en) * | 2007-03-16 | 2010-09-30 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
| WO2008143440A1 (en) | 2007-05-17 | 2008-11-27 | Lg Chem, Ltd. | New anthracene derivatives and organic electronic device using the same |
| UY31272A1 (es) * | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| AU2008286760A1 (en) | 2007-08-15 | 2009-02-19 | Memory Pharmaceuticals Corporation | 3' substituted compounds having 5-HT6 receptor affinity |
| WO2009029617A1 (en) * | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
| KR100974562B1 (ko) * | 2007-12-31 | 2010-08-06 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자 |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| EP2384337A1 (en) * | 2009-01-05 | 2011-11-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants |
| ES2630226T3 (es) * | 2009-01-06 | 2017-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Un agente agotador de células B para el tratamiento de la aterosclerosis |
| WO2010079123A2 (en) * | 2009-01-06 | 2010-07-15 | Dsm Ip Assets B.V. | Process for resveratrol intermediate |
| HRP20191460T1 (hr) | 2009-06-12 | 2019-11-15 | Abivax | Spojevi korisni za liječenje raka |
| CU24245B1 (es) | 2009-06-12 | 2017-02-02 | Centre Nat Rech Scient | QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADAS |
| EP2266972A1 (en) | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
| WO2010151755A2 (en) | 2009-06-25 | 2010-12-29 | The Brigham And Women's Hospital, Inc. | TREATMENT OF INFLAMMATORY DISEASES USING miR-124 |
| EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| CA2887066A1 (en) | 2012-10-04 | 2014-04-10 | Oyagen, Inc. | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| JP2015120566A (ja) * | 2013-12-20 | 2015-07-02 | ニチユ三菱フォークリフト株式会社 | 荷役車両 |
-
2010
- 2010-06-14 CU CUP2015000024A patent/CU24245B1/es unknown
- 2010-06-14 US US13/377,745 patent/US20120277230A1/en not_active Abandoned
- 2010-06-14 PL PL10757474.1T patent/PL2440547T3/pl unknown
- 2010-06-14 CN CN201080032055.0A patent/CN102596935B/zh active Active
- 2010-06-14 DK DK10728368.1T patent/DK2440545T3/da active
- 2010-06-14 CN CN201080032045.7A patent/CN102625804B/zh active Active
- 2010-06-14 EP EP10757474.1A patent/EP2440547B1/en active Active
- 2010-06-14 FI FIEP19157827.7T patent/FI3517534T3/fi active
- 2010-06-14 MX MX2015016293A patent/MX364989B/es unknown
- 2010-06-14 CA CA2764024A patent/CA2764024C/en active Active
- 2010-06-14 CN CN201510023124.6A patent/CN104844570B/zh active Active
- 2010-06-14 DK DK19157827.7T patent/DK3517534T3/da active
- 2010-06-14 SI SI201032127T patent/SI2440547T1/sl unknown
- 2010-06-14 CU CUP2011000229A patent/CU24124B1/es active IP Right Grant
- 2010-06-14 CN CN201510020820.1A patent/CN104945378B/zh active Active
- 2010-06-14 HU HUE10728368A patent/HUE045548T2/hu unknown
- 2010-06-14 BR BR122019013686-6A patent/BR122019013686B1/pt active IP Right Grant
- 2010-06-14 KR KR1020177021820A patent/KR101863021B1/ko active Active
- 2010-06-14 US US13/377,760 patent/US9145367B2/en active Active
- 2010-06-14 HR HRP20230248TT patent/HRP20230248T1/hr unknown
- 2010-06-14 DK DK10757474.1T patent/DK2440547T3/da active
- 2010-06-14 KR KR1020197004605A patent/KR102016890B1/ko active Active
- 2010-06-14 KR KR1020197004608A patent/KR102016893B1/ko active Active
- 2010-06-14 ES ES10728369T patent/ES2940885T3/es active Active
- 2010-06-14 WO PCT/IB2010/052651 patent/WO2010143169A2/en not_active Ceased
- 2010-06-14 CA CA2764026A patent/CA2764026C/en active Active
- 2010-06-14 CN CN201510021597.2A patent/CN104945379B/zh active Active
- 2010-06-14 ES ES10757474T patent/ES2938532T3/es active Active
- 2010-06-14 MX MX2016007353A patent/MX367601B/es unknown
- 2010-06-14 PT PT10728368T patent/PT2440545T/pt unknown
- 2010-06-14 PT PT191578277T patent/PT3517534T/pt unknown
- 2010-06-14 KR KR1020127000914A patent/KR20120051643A/ko not_active Ceased
- 2010-06-14 CA CA3070823A patent/CA3070823C/en active Active
- 2010-06-14 KR KR1020197004604A patent/KR102016889B1/ko active Active
- 2010-06-14 ES ES19157827T patent/ES2985082T3/es active Active
- 2010-06-14 JP JP2012514587A patent/JP5905385B2/ja active Active
- 2010-06-14 KR KR1020127000915A patent/KR101789275B1/ko active Active
- 2010-06-14 AU AU2010258214A patent/AU2010258214B2/en active Active
- 2010-06-14 PL PL10728369.9T patent/PL2440546T3/pl unknown
- 2010-06-14 MX MX2018009425A patent/MX373120B/es unknown
- 2010-06-14 EP EP19157824.4A patent/EP3521283B1/en active Active
- 2010-06-14 KR KR1020177031675A patent/KR101897221B1/ko active Active
- 2010-06-14 WO PCT/IB2010/052650 patent/WO2010143168A2/en not_active Ceased
- 2010-06-14 BR BRPI1012892A patent/BRPI1012892B8/pt active IP Right Grant
- 2010-06-14 PL PL19157827.7T patent/PL3517534T3/pl unknown
- 2010-06-14 FI FIEP10757474.1T patent/FI2440547T3/fi active
- 2010-06-14 KR KR1020127000916A patent/KR101769616B1/ko active Active
- 2010-06-14 MX MX2015016292A patent/MX364280B/es unknown
- 2010-06-14 PT PT107283699T patent/PT2440546T/pt unknown
- 2010-06-14 LT LTEPPCT/IB2010/052651T patent/LT2440547T/lt unknown
- 2010-06-14 EP EP22193611.5A patent/EP4198022A1/en active Pending
- 2010-06-14 HR HRP20240582TT patent/HRP20240582T1/hr unknown
- 2010-06-14 CN CN201080032036.8A patent/CN102574835B/zh active Active
- 2010-06-14 FI FIEP10728369.9T patent/FI2440546T3/fi active
- 2010-06-14 WO PCT/IB2010/052652 patent/WO2010143170A2/en not_active Ceased
- 2010-06-14 TR TR2019/10781T patent/TR201910781T4/tr unknown
- 2010-06-14 KR KR1020197004607A patent/KR102016892B1/ko active Active
- 2010-06-14 KR KR1020187025623A patent/KR101982461B1/ko active Active
- 2010-06-14 CA CA2764027A patent/CA2764027C/en active Active
- 2010-06-14 CN CN201710158474.2A patent/CN106928194B/zh active Active
- 2010-06-14 MX MX2015016291A patent/MX364279B/es unknown
- 2010-06-14 HU HUE10757474A patent/HUE061262T2/hu unknown
- 2010-06-14 BR BR122019013687A patent/BR122019013687B1/pt active IP Right Grant
- 2010-06-14 PL PL10728368T patent/PL2440545T3/pl unknown
- 2010-06-14 EP EP19157827.7A patent/EP3517534B1/en active Active
- 2010-06-14 CN CN202110307700.5A patent/CN113004249A/zh active Pending
- 2010-06-14 CN CN201710158473.8A patent/CN106928205B/zh active Active
- 2010-06-14 CU CU2011000230A patent/CU24093B1/es active IP Right Grant
- 2010-06-14 MX MX2011013120A patent/MX338823B/es active IP Right Grant
- 2010-06-14 KR KR1020187025626A patent/KR101982463B1/ko active Active
- 2010-06-14 CN CN201410106644.9A patent/CN103948594B/zh active Active
- 2010-06-14 EP EP10728368.1A patent/EP2440545B1/en active Active
- 2010-06-14 PT PT107574741T patent/PT2440547T/pt unknown
- 2010-06-14 CN CN201710122014.4A patent/CN106905232B/zh active Active
- 2010-06-14 CN CN201910120757.7A patent/CN109776496B/zh active Active
- 2010-06-14 CN CN201510023109.1A patent/CN104844510B/zh active Active
- 2010-06-14 US US13/377,753 patent/US20120329796A1/en not_active Abandoned
- 2010-06-14 AU AU2010258294A patent/AU2010258294B2/en not_active Ceased
- 2010-06-14 CA CA2965791A patent/CA2965791C/en active Active
- 2010-06-14 DK DK10728369.9T patent/DK2440546T3/da active
- 2010-06-14 MX MX2011013122A patent/MX340095B/es active IP Right Grant
- 2010-06-14 KR KR1020197004606A patent/KR102016891B1/ko active Active
- 2010-06-14 MX MX2015016290A patent/MX364282B/es unknown
- 2010-06-14 BR BRPI1010768A patent/BRPI1010768C8/pt active IP Right Grant
- 2010-06-14 MX MX2011013119A patent/MX353776B/es active IP Right Grant
- 2010-06-14 KR KR1020187025625A patent/KR101982462B1/ko active Active
- 2010-06-14 HR HRP20230143TT patent/HRP20230143T1/hr unknown
- 2010-06-14 JP JP2012514586A patent/JP5826745B2/ja active Active
- 2010-06-14 CU CU2011000228A patent/CU24461B1/es unknown
- 2010-06-14 ES ES10728368T patent/ES2736198T3/es active Active
- 2010-06-14 BR BRPI1010772A patent/BRPI1010772B8/pt active IP Right Grant
- 2010-06-14 RU RU2011149571/04A patent/RU2567752C2/ru active
- 2010-06-14 MX MX2016003039A patent/MX359575B/es unknown
- 2010-06-14 JP JP2012514585A patent/JP6041671B2/ja active Active
- 2010-06-14 EP EP10728369.9A patent/EP2440546B1/en active Active
- 2010-06-14 AU AU2010258295A patent/AU2010258295B2/en active Active
- 2010-06-14 KR KR1020187025624A patent/KR101973348B1/ko active Active
-
2011
- 2011-12-08 ZA ZA2011/09031A patent/ZA201109031B/en unknown
- 2011-12-08 ZA ZA2011/09032A patent/ZA201109032B/en unknown
-
2013
- 2013-11-22 US US14/087,762 patent/US9108919B2/en active Active
-
2014
- 2014-04-18 US US14/256,334 patent/US9908869B2/en active Active
-
2015
- 2015-04-27 JP JP2015090437A patent/JP2015155453A/ja active Pending
- 2015-06-15 JP JP2015120567A patent/JP6158250B2/ja active Active
- 2015-06-15 JP JP2015120566A patent/JP2015187150A/ja not_active Withdrawn
- 2015-06-15 JP JP2015120568A patent/JP6158251B2/ja active Active
- 2015-07-01 US US14/789,149 patent/US9637475B2/en active Active
- 2015-07-01 US US14/789,250 patent/US10017498B2/en active Active
-
2019
- 2019-10-18 JP JP2019191500A patent/JP7042245B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2440547T (lt) | Naujos cheminės molekulės, kurios slopina splaisingo mechanizmą, skirtos gydyti ligas, atsirandančias dėl splaisingo defektų | |
| PL2235000T3 (pl) | Cząsteczki chemiczne hamujące mechanizm splicingu do leczenia chorób wynikających z nieprawidłowości splicingu | |
| GB0910003D0 (en) | Novel compounds for the treatment of neurodegenerative diseases | |
| EP2262364A4 (en) | OXADIAZOANTHRACEN COMPOUNDS FOR THE TREATMENT OF DIABETES | |
| LT2349132T (lt) | Aparatas gerl gydymui | |
| EP2464219A4 (en) | MULTI-TRANSGENIC PIGS FOR DIABETES TREATMENT | |
| PL2303021T3 (pl) | Związki do leczenia nowotworu | |
| GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
| HUE045367T2 (hu) | Kombinált terápia diabétesz kezelésére | |
| IL207640A0 (en) | Process for the iodination of aromatic compounds | |
| IL253293B (en) | Desferrioxamine complexes of metals for the treatment of diseases related to the immune system | |
| ZA201107449B (en) | Compounds for the treatment of metabolic disorders | |
| GB0904287D0 (en) | Compounds for the treatment of metabolic disorders | |
| ZA201008222B (en) | Process for the synthesis of arformoterol | |
| IL215685A0 (en) | Process for the iodination of aromatic compounds | |
| IL207520A (en) | Carboxamide-heteroaryl derivatives for the treatment of diabetes | |
| GB0904284D0 (en) | Compounds for the treatment of metabolic disorders | |
| PT2498603T (pt) | Utilização de agentes antibacterianos para o tratamento de afecções relacionadas com o epitélio | |
| IL214906A0 (en) | Process for the prepartion of ajoene | |
| IL210066A0 (en) | Novel ortho-aminoanilides for the treatment of cancer | |
| EP2484385A4 (en) | COMPOSITION FOR THE TREATMENT OF PANCREATIC CANCER | |
| BR112012002267A2 (pt) | compostos para o tratamento de inflamação. | |
| PL2326551T3 (pl) | Urządzenie do uzdatniania ścieków | |
| EP2470495A4 (en) | PROCESS FOR NITRATION OF O-XYLENE AND SIMILAR COMPOUNDS | |
| GB0713541D0 (en) | Process for the coloration of substances |